657 related articles for article (PubMed ID: 18778390)
1. The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study.
Roux P; Carrieri MP; Villes V; Dellamonica P; Poizot-Martin I; Ravaux I; Spire B;
Addiction; 2008 Nov; 103(11):1828-36. PubMed ID: 18778390
[TBL] [Abstract][Full Text] [Related]
2. Retention in opioid substitution treatment: a major predictor of long-term virological success for HIV-infected injection drug users receiving antiretroviral treatment.
Roux P; Carrieri MP; Cohen J; Ravaux I; Poizot-Martin I; Dellamonica P; Spire B
Clin Infect Dis; 2009 Nov; 49(9):1433-40. PubMed ID: 19807275
[TBL] [Abstract][Full Text] [Related]
3. Adherence to HIV treatment among IDUs and the role of opioid substitution treatment (OST).
Spire B; Lucas GM; Carrieri MP
Int J Drug Policy; 2007 Aug; 18(4):262-70. PubMed ID: 17689374
[TBL] [Abstract][Full Text] [Related]
4. Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy.
Palepu A; Tyndall MW; Joy R; Kerr T; Wood E; Press N; Hogg RS; Montaner JS
Drug Alcohol Depend; 2006 Sep; 84(2):188-94. PubMed ID: 16542797
[TBL] [Abstract][Full Text] [Related]
5. Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy.
Bouhnik AD; Préau M; Vincent E; Carrieri MP; Gallais H; Lepeu G; Gastaut JA; Moatti JP; Spire B;
Antivir Ther; 2005; 10(1):53-61. PubMed ID: 15751763
[TBL] [Abstract][Full Text] [Related]
6. Key findings from the WHO collaborative study on substitution therapy for opioid dependence and HIV/AIDS.
Lawrinson P; Ali R; Buavirat A; Chiamwongpaet S; Dvoryak S; Habrat B; Jie S; Mardiati R; Mokri A; Moskalewicz J; Newcombe D; Poznyak V; Subata E; Uchtenhagen A; Utami DS; Vial R; Zhao C
Addiction; 2008 Sep; 103(9):1484-92. PubMed ID: 18636999
[TBL] [Abstract][Full Text] [Related]
7. The impact of ongoing illicit drug use on methadone adherence in illicit drug users receiving treatment for HIV in a directly observed therapy program.
Raffa JD; Grebely J; Tossonian H; Wong T; Viljoen M; Khara M; Mead A; McLean M; Duncan F; Petkau AJ; DeVlaming S; Conway B
Drug Alcohol Depend; 2007 Jul; 89(2-3):306-9. PubMed ID: 17383117
[TBL] [Abstract][Full Text] [Related]
8. Feasibility of buprenorphine and methadone maintenance programmes among users of home made opioids in Ukraine.
Schaub M; Chtenguelov V; Subata E; Weiler G; Uchtenhagen A
Int J Drug Policy; 2010 May; 21(3):229-33. PubMed ID: 19926271
[TBL] [Abstract][Full Text] [Related]
9. Psychosocial determinants of adherence to highly active antiretroviral therapy among injection drug users in Vancouver.
Kerr T; Palepu A; Barness G; Walsh J; Hogg R; Montaner J; Tyndall M; Wood E
Antivir Ther; 2004 Jun; 9(3):407-14. PubMed ID: 15259903
[TBL] [Abstract][Full Text] [Related]
10. Factors associated with non-adherence to long-term highly active antiretroviral therapy: a 10 year follow-up analysis with correction for the bias induced by missing data.
Protopopescu C; Raffi F; Roux P; Reynes J; Dellamonica P; Spire B; Leport C; Carrieri MP;
J Antimicrob Chemother; 2009 Sep; 64(3):599-606. PubMed ID: 19602563
[TBL] [Abstract][Full Text] [Related]
11. Self-reported side-effects of anti-retroviral treatment among IDUs: a 7-year longitudinal study (APROCO-COPILOTE COHORT ANRS CO-8).
Carrieri MP; Villes V; Raffi F; Protopopescu C; Preau M; Salmon D; Taieb A; Lang JM; Verdon R; Chene G; Spire B;
Int J Drug Policy; 2007 Aug; 18(4):288-95. PubMed ID: 17689377
[TBL] [Abstract][Full Text] [Related]
12. Survival of HIV-infected injection drug users (IDUs) in the highly active antiretroviral therapy era, relative to sex- and age-specific survival of HIV-uninfected IDUs.
Muga R; Langohr K; Tor J; Sanvisens A; Serra I; Rey-Joly C; Muñoz A
Clin Infect Dis; 2007 Aug; 45(3):370-6. PubMed ID: 17599317
[TBL] [Abstract][Full Text] [Related]
13. Buprenorphine in primary care: risk factors for treatment injection and implications for clinical management.
Roux P; Villes V; Blanche J; Bry D; Spire B; Feroni I; Carrieri MP
Drug Alcohol Depend; 2008 Sep; 97(1-2):105-13. PubMed ID: 18479840
[TBL] [Abstract][Full Text] [Related]
14. Prescribers' perceptions of the diversion and injection of medication by opioid substitution treatment patients.
Larance B; Degenhardt L; O'Brien S; Lintzeris N; Winstock A; Mattick RP; Bell J; Ali R
Drug Alcohol Rev; 2011 Nov; 30(6):613-20. PubMed ID: 21355939
[TBL] [Abstract][Full Text] [Related]
15. Highly active antiretroviral therapy (HAART) among HIV-infected drug users: a prospective cohort study of sexual risk and injecting behaviour.
Smit C; Lindenburg K; Geskus RB; Brinkman K; Coutinho RA; Prins M
Addiction; 2006 Mar; 101(3):433-40. PubMed ID: 16499516
[TBL] [Abstract][Full Text] [Related]
16. Oral lesions as clinical markers of highly active antiretroviral therapy failure: a nested case-control study in Mexico City.
Ramírez-Amador V; Ponce-de-León S; Anaya-Saavedra G; Crabtree Ramírez B; Sierra-Madero J
Clin Infect Dis; 2007 Oct; 45(7):925-32. PubMed ID: 17806063
[TBL] [Abstract][Full Text] [Related]
17. Health related quality of life among both current and former injection drug users who are HIV-infected.
Préau M; Protopopescu C; Spire B; Sobel A; Dellamonica P; Moatti JP; Carrieri MP;
Drug Alcohol Depend; 2007 Jan; 86(2-3):175-82. PubMed ID: 16930864
[TBL] [Abstract][Full Text] [Related]
18. Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users.
Wood E; Montaner JS; Yip B; Tyndall MW; Schechter MT; O'Shaughnessy MV; Hogg RS
CMAJ; 2003 Sep; 169(7):656-61. PubMed ID: 14517122
[TBL] [Abstract][Full Text] [Related]
19. Predictors of short-term success of antiretroviral therapy in HIV infection.
Oette M; Kroidl A; Göbels K; Stabbert A; Menge M; Sagir A; Kuschak D; O'hanley T; Bode JG; Häussinger D
J Antimicrob Chemother; 2006 Jul; 58(1):147-53. PubMed ID: 16687458
[TBL] [Abstract][Full Text] [Related]
20. Barriers and facilitators to primary care or human immunodeficiency virus clinics providing methadone or buprenorphine for the management of opioid dependence.
Turner BJ; Laine C; Lin YT; Lynch K
Arch Intern Med; 2005 Aug 8-22; 165(15):1769-76. PubMed ID: 16087826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
